Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study (Q35087639)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

10

object named as

Jaime F Modiano

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

author name string

Cheryl A London

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Luis Feo Bernabe

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sandra Barnard

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

William C Kisseberth

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Antonella Borgatti

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Mike Henson

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Heather Wilson

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Kiersten Jensen

8

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Daisuke Ito

9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Misty D Bear

11

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Michael L Pennell

12

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Jean-Richard Saint-Martin

13

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Dilara McCauley

14

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Michael Kauffman

15

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sharon Shacham

16

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

language of work or name

0 references

publication date

4 February 2014

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

e87585

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

copyright license

Creative Commons Attribution 4.0 International

4 February 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Sequence and structural analyses of nuclear export signals in the NESdb database

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

NESdb: a database of NES-containing CRM1 cargoes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

The CRM1 nuclear export protein in normal development and disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Authentication of primordial characteristics of the CLBL-1 cell line prove the integrity of a canine B-cell lymphoma in a murine in vivo model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Nuclear export of proteins and drug resistance in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Ran-dependent nuclear export mediators: a structural perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Identification of nuclear export inhibitors with potent anticancer activity in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

CRM1-mediated nuclear export of proteins and drug resistance in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Restoration of p53 function leads to tumour regression in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Modeling the therapeutic efficacy of p53 restoration in tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Kinetic and molecular analysis of nuclear export factor CRM1 association with its cargo in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

CRM1 is responsible for intracellular transport mediated by the nuclear export signal

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

CRM1 is an export receptor for leucine-rich nuclear export signals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Phase I trial of elactocin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

A possible autocrine role for interleukin-6 in two lymphoma cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Establishment of two dog mastocytoma cell lines in continuous culture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Regulation of interleukin-6 expression in the lymphoma cell line OCI-LY3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

8 July 2018

Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0087585

21 January 2018

Development of a questionnaire assessing health‐related quality‐of‐life in dogs and cats with cancer

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0087585

21 January 2018

Small Sample Inference for Fixed Effects from Restricted Maximum Likelihood

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0087585

21 January 2018

Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

27 September 2018

Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913620

27 September 2018

CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24503695

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0087585

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

2014PLoSO...987585L

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35087639&oldid=1961048380"